|
No images? Click here
Three journeys that comprehensively cover the use of RhD immunoglobulinOur Antenatal management of RhD negative women eLearn is one with a difference in that it highlights a series of patient-focused clinical pathways - Zahra, Lucia and Jayne's. Do you care for RhD negative women in pregnancy? If so, then you need to visit our new-look, interactive eLearn which has been developed to demonstrate the best practice management of RhD negative women during pregnancy.
A series of three clinical scenarios will provide you with everything you need to know about the pathophysiology of Haemolytic disease of the fetus and newborn (HDFN), the laboratory investigations required in the management of RhD negative women and the key requirements for the safe administration and appropriate use of RhD immunoglobulin. Prophylactic RhD immunoglobulin is offered routinely to RhD negative women during pregnancy and following the birth of a RhD positive baby to help prevent HDFN. Before the routine administration of RhD immunoglobulin, HDFN was a significant cause of fetal and neonatal morbidity and mortality. As a result, the new eLearn will be an important tool to maintain awareness and engagement with clinicians, particularly midwives, about antenatal management. This new resource is a patient-focused refresh of the RhD immunoglobulin clinical modules eLearn. By answering the assessment questions and feedback form at the end, you'll receive a certificate of completion.
Get reacquainted with the High Ferritin AppLifeblood's High Ferritin App has new functionality where referrals can now be submitted electronically through secure file transfer. There's no need for log-ins or passwords due to the fact that no information will be stored - all you need to do is simply complete the referral and hit send. The High Ferritin App is a web-based tool that enables doctors to determine the eligibility of patients and place referrals to undertake therapeutic venesection at Lifeblood, and provides education on possible causes of high ferritin. Patients approved by the app need to be regularly reviewed by their treating clinician for continued suitability for therapeutic venesection, unless they are on a 3-monthly maintenance venesection schedule. Annual review and referral via the app is required for patients with polycythaemia and porphyria cutanea tarda, along with those haemochromatosis patients with compensated cirrhosis. Lifeblood will no longer be able to send any reminders regarding expired referrals, so you'll need to take note when a new referral will be required. The algorithm in the app was developed in consultation with Professor John Olynyk, an expert in the field of iron disorders, and has been approved by the Gastroenterological Society of Australia and the Haematology Society of Australia and New Zealand. It's also endorsed by Haemochromatosis Australia and has been developed in accordance with federal privacy legislation and the national privacy principles. Full marks for BLOOD 2022This year's BLOOD 2022 Conference (11-14 September) was our first major post-COVID-19 physical event engaging with health professionals to promote our transfusion resources. There was a great deal of engagement, conversations about collaboration, feedback on resources, and around 2,000 items of collateral distributed. As a result of this feedback and demand, the tailored resources developed to help nurses in rural and regional Western Australia as part of the collaborative effort with WA Country Health Service, will be re-worked so they can be rolled-out nationally. Also presented and launched was our Iron optimisation in maternity resource. The flowcharts in this resource provide healthcare professionals involved in antenatal care with practical guidance on the identification and management of iron deficiency, independent of anaemia, in pregnancy. The impact of obstetric iron deficiency in the absence of anaemia is underappreciated and, as a result, goes largely undiagnosed and untreated. However, it has the potential to affect both maternal wellbeing and fetal development with concerns that the physical, psychological and neurocognitive consequences of perinatal iron deficiency might persist despite iron replacement in early life.
Do you have something to say?The National Blood Authority (NBA) is inviting public consultation on the draft patient blood management guideline for people with critical bleeding. A review of the Patient Blood Management Guidelines: Module 1 – Critical Bleeding/Massive Transfusion was undertaken to update and enhance the evidence base and to ensure that the clinical guidance relating to the appropriate use of blood components and strategies that aim to minimise blood loss remain accurate and current. The NBA is using this opportunity to present the draft guideline to a wide clinical audience encompassing a broad range of expertise, and to invite interested groups, organisations and individuals to provide their feedback. The closing date for submissions is COB Wednesday 9 November 2022. Topics trending at LifebloodEvery month one of our transfusion experts Dr Tamar Kapterian points us to the latest journal articles being discussed at Lifeblood. Guidance for transfusion management in patients receiving magrolimab therapy (anti-CD47 monoclonal antibody)Magrolimab (Hu5F9-G4), an anti-CD47 IgG4 monoclonal antibody, has recently emerged as a potential therapeutic target in several haematological malignancies. However, due to the ubiquitous expression of CD47 on red cells, treatment with magrolimab causes interference in pretransfusion immunohaematology investigations. Of interest, is a position paper recently published (accepted manuscript) in the Internal Medicine Journal by Tan and colleagues which provides clinical and laboratory recommendations for transfusion management in patients receiving magrolimab therapy in the Australian setting. ISBT Working Party on Red Cell Immunogenetics and Blood Group Terminology Report The International Society of Blood Transfusion (ISBT) Working Party (WP) for Red Cell Immunogenetics and Blood Group Terminology is responsible for the approval and naming of blood group systems and antigens. Recently published as an early view article is the WP report summarising the evidence presented in ratifying seven new blood group systems and 15 new antigens. Over the four business meetings (held between 2019-2021), a total of seven new blood group systems were registered; KANNO (defined numerically as ISBT 037), SID (038), CTL2 (039), PEL (040), MAM (041), EMM (042) and ABCC1 (043) (only CTL2 and ABCC1 comprised de novo antigens). An additional 15 blood group antigens were also added to the existing blood group systems over the course of the meetings: MNS (002), RH (004), LU (005), DI (010), SC (013), GE (020), KN (022), JMH (026) and RHAG (030). Upcoming webinarCOVID-19 lessons and learnings for a large-scale organisation The global COVID-19 pandemic has had a major impact on organisational, professional and personal resilience. Global, national and local supply chains have been stretched. Lockdowns and other restrictions have impacted operational functions and highlighted the need to ensure the welfare of staff as the organisation adapts to changing circumstances and working environments. 14 November 2022, 1.00–2.00 pm AEST |